Bryxta 400mg Injection

About this medicine

Bryxta 400mg Injection (BEVACIZUMAB)is a prescription oncology medicine. Below is educational product information — follow your doctor's advice for dose and use.

Bryxta 400mg Injection is an anticancer medicine manufactured by Zydus and contains Bevacizumab 400mg as its active ingredient. It belongs to a group of medicines known as anti-angiogenic agents. Bevacizumab works by blocking the growth of new blood vessels that tumors need for their oxygen and nutrient supply, which can help slow the progression of cancer. Bryxta 400mg may be used alongside other cancer treatments for several types of malignancies, including colorectal cancer, lung cancer, metastatic breast cancer, kidney cancer, cervical cancer, brain tumors, and cancers affecting the ovary, fallopian tube, or peritoneum. The appropriate Bryxta 400mg dosage varies depending on the type of cancer, treatment regimen, and the patient's overall medical condition. It is given as an intravenous infusion under the supervision of a qualified healthcare professional. Your oncologist will determine the appropriate dose, frequency, and duration of treatment. Some patients may experience side effects such as fatigue, constipation, reduced appetite, or skin-related reactions. Other adverse effects are also possible, so patients should inform their doctor about any unusual or persistent symptoms during treatment. For genuine medication and appropriate storage and handling, Bryxta 400mg should be obtained through licensed pharmacies or authorized medicine suppliers. The suitability of alternatives or substitutes should be determined by the treating oncologist based on the patient's condition and prescribed treatment plan.